Antiplatelet therapy: Aspirin, ticlopidine/clopidogrel, and anti- integrin agents

D. C. Calverley, G. J. Roth

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Aspirin is the most widely employed antithrombotic agent in use today and has a proven role in the prevention and acute management of atherosclerosis-associated arterial thrombotic events. More recently developed antiplatelet agents have been found to have specific prophylactic roles associated with percutaneous coronary intervention and other clinical settings. This article outlines pharmacologic considerations and current clinical knowledge relevant to the use of aspirin, ticlopidine, clopidogrel, and the GPIIbIIIa antagonists in the management of thrombotic disorders.

Original languageEnglish (US)
Pages (from-to)1231-1249
Number of pages19
JournalHematology/Oncology Clinics of North America
Issue number6
StatePublished - 1998
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Antiplatelet therapy: Aspirin, ticlopidine/clopidogrel, and anti- integrin agents'. Together they form a unique fingerprint.

Cite this